Genus Regulatory News (GNS)

17 Jan 2008 07:00

Genus PLC17 January 2008 For immediate release 17 January 2008 Genus plc ("Genus" or "the Company") Board Changes Genus, a world leading animal genetics company, announces that Nigel Turner willbe joining the Board as senior independent non-executive director with effectfrom today. Nigel (aged 58), was Chairman of Numis Securities Ltd and Deputy Chairman ofNumis Corporation plc from December 2005 to November 2007. Previously he was Vice Chairman of ABN AMRO's Wholesale and Investment Bank inwhich he had specific responsibility for the Global Corporate Finance and Equitybusinesses. He joined the Dutch bank in 2000 from Lazard, where he was a partnerfor 15 years and sat on its Supervisory Board. Nigel will chair the Company's Remuneration Committee and be a member of theCompany's Audit and Nomination Committees. Genus today also announces the retirement from the Board, with effect from today, of Edwin White. At the Company's Annual General Meeting held in November 2007, the Chairman announced that Edwin had indicated his intention to leave the Board, having been a Board member since the Company became publicly quoted seven years ago. John Hawkins, Chairman of Genus, commented: "We are delighted to welcome Nigel to the Board. With Genus' recent move to the Official List, Nigel's considerable experience will greatly benefit Genus in its next stage of development as a listed company." "I would also like to take this opportunity, on behalf of the Board, to thank Edwin for his valuable knowledge and contribution to the growth and success of Genus, and to wish him well in his retirement." There are no further details required to be disclosed under 9.6.13R of theListing Rules of the UK Listing Authority. For further information please contact: Genus plc Tel: 01256 345970John Hawkins, ChairmanRichard Wood, Chief Executive Buchanan Communications Tel: 020 7466 5000Charles Ryland / Suzanne Brocks About Genus Genus sells added value products for livestock farming and food producers bycreating advances to animal breeding through biotechnology. Its non-GeneticallyModified Organism (GMO) technology is applicable across all livestock speciesbut is only commercialised by Genus in the bovine and porcine farming sectors. Genus' worldwide sales are made in seventy countries under the trade marks "ABS"(dairy and beef cattle) and "PIC" (pigs) and comprise semen and breeding animalswith superior genetics to those animals currently in production. Customers useGenus genetics in their herds to produce offspring with greater productionefficiency, milk and meat output and quality. These offspring are used to supplythe global dairy and meat supply chain. Genus' competitive edge has been created from the ownership and control ofproprietary lines of breeding animals, the biotechnology used to improve themand the Group's global production and distribution network. Headquartered in Basingstoke, England, Genus companies operate in 30 countrieson six continents, with research laboratories located in Madison, USA. This information is provided by RNS The company news service from the London Stock Exchange